leisure time -WSS

leisure time

author：knowledge 2025-09-28 02:32:34 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Editas, Vertex strike deal on CRISPR

leisure time

WSS

Military medical care influenced by rank and race, new study finds

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

David Ricks of Eli Lilly: best biopharma CEO of 2023

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Readers respond to H5N1 and livestock movements, and more

explore

leisure time

The next ALS data readout — overdue but important

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

At least 13 dead in Texas as scorching temps continue

It's time to retire 'poor historian' from clinicians' vocabularies

Jerome Adams on the need for new antivirals for Covid

Big Tobacco's 'harm reduction': Is it for real, or a sham?

23andMe had bad news about my health. I wish a person had delivered it

Data integrity in scientific journals requires "effort" by publishers, institutions

How one medical school became remarkably diverse

Readout LOUD podcast: Live from STAT Breakthrough Summit West

explore

Three trends to watch in biotech in 2024

In Spain, a hospital brews its own CAR

Carvykti CAR

HIV vaccine remains elusive. Immunologists keep trying new ideas

Second House panel advances two

Can sheer will power keep patients alive in their dying hours?

leisure time

leisure time

knowledge

leisure time